Interview with Andrew Giddy, CEO, Nucleus Network
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
Address: 5th Floor, Burnet Tower, AMREP Precinct ,89 Commercial Road,Melbourne, Victoria, Australia, 3004
Tel: + 613 9076 8900
Web: http://www.nucleusnetwork.com.au/page.aspx?54
Nucleus Network is committed to operational and service excellence. All Nucleus Network’s clinical research is conducted in accordance with internationallyrecognised standards of Good Clinical Practice. Data generated is accepted by all major regulatory jurisdictions including FDA, EMEA and TGA.
Whether you work with Nucleus Network clinical research team, education or consulting personnel, Nucleus Network are committed to providing high quality services and adherence to ethical principles. It is Nucleus Network’s aim to deliver services in a timely and cost-effective manner and to give customers peace of mind. To achieve this, Nucleus Network uses the latest technologies within a coordinated and collaborative framework.
Nucleus Network is committed to quality and continuous improvement in order to meet our clients’ needs for timeliness and high quality data.
Research, Clinical trials
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of…
To begin, would you please introduce GMIA to Pharmaceutical Executive readers? The GMIA is an industry organization. Its six members are: Alphapharm, Apotex, Genepharm, Hospira, Sandoz and Sigma. The GMiA…
How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well in the country for…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines…
To begin, would you please give a brief introduction to the PBAC? The PBAC is a statutory committee of government first developed in Australia in the 1940s, which advises the…
The Ministry for Innovation, Industry, Science and Research was created in December 2007 with the election of the Labor government. To begin, would you please give a brief introduction to…
Would you please introduce Pierre Fabre to our readers? Pierre Fabre Medicament Australia Pty Limited was established in Australia in late 2001, and is a fully owned subsidiary of the…
The Australian pharmaceutical sector has seen recent innovations through PBS reform and various working groups shaping the future of the industry. Can you comment on how Datapharm is reacting to…
What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the national industry association for innovative pharmaceutical companies. . Just about every company engaged in…
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
See our Cookie Privacy Policy Here
